Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
10/24/26 Pfizer (PFE) atirmociclib for HR+/HER2- Breast Cancer Subscribers Only Subscribers Only Subscribers Only
10/23/26 Johnson & Johnson (JNJ) Erleada for Prostate Cancer Subscribers Only Subscribers Only Subscribers Only
10/23/26 Marengo invikafusp alfa for Colorectal Cancer (CRC) Subscribers Only Subscribers Only Subscribers Only
10/23/26 Marengo invikafusp alfa for Solid Tumors Subscribers Only Subscribers Only Subscribers Only
10/23/26 Perspective Therapeutics (CATX) VMT-α-NET for Neuroendocrine Tumors (NET) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
07/31/2025 Subscribers Only Subscribers Only Regulatory - sNDA/sBLA Filing
07/31/2025 Subscribers Only Subscribers Only Regulatory - IND/CTA Filing
10/28/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/31/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/11/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update